MarketCap
Facebook
X
Telegram
Affimed N.V. Market Cap | AFMD
As of November 08, 2026 Affimed N.V. has a market cap of $ 21.5 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Affimed N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 527 M | 473 M | 152 M | 212 M | 93 M | 66.5 M | 90.8 M | 136 M | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 527 M | 66.5 M | 219 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Midatech Pharma plc
MTP
|
1.44 B | - | -18.52 % | $ 27.3 M |  Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
100 M | $ 0.69 | 11.43 % | $ 73.6 M | Britain |
 |
MorphoSys AG
MOR
|
624 M | - | 2.43 % | $ 254 M |  Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
167 M | - | -1.58 % | $ 28.1 M |  China |
 |
Celyad Oncology SA
CYAD
|
10.6 M | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
123 M | $ 1.63 | 0.18 % | $ 90.4 M |  USA |
 |
Gracell Biotechnologies
GRCL
|
1.99 B | - | - | $ 3.37 B | China |
 |
Stoke Therapeutics
STOK
|
2.01 B | $ 26.51 | 1.69 % | $ 1.57 B | USA |
 |
Sutro Biopharma
STRO
|
181 M | $ 9.57 | 4.08 % | $ 81.3 M | USA |
 |
Silence Therapeutics plc
SLN
|
812 M | $ 19.73 | 0.03 % | $ 2.8 B | Britain |
 |
Taysha Gene Therapies
TSHA
|
1.46 B | $ 4.34 | 6.11 % | $ 1.39 B | USA |
 |
Soligenix
SNGX
|
6.12 M | $ 0.34 | 0.54 % | $ 1.76 M | USA |
 |
Spruce Biosciences
SPRB
|
47.6 M | $ 46.46 | 8.78 % | $ 35.6 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
3.11 B | $ 26.14 | -2.24 % | $ 1.48 B | USA |
 |
Galapagos NV
GLPG
|
1.91 B | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
1.17 B | $ 4.82 | 9.93 % | $ 1.07 B | USA |
 |
Viking Therapeutics
VKTX
|
3.18 B | $ 26.86 | 4.15 % | $ 3.03 B | USA |
 |
Teligent, Inc.
TLGT
|
5.03 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
427 M | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
4.34 B | $ 59.78 | 3.1 % | $ 8.63 B | USA |
 |
Aphria Inc.
APHA
|
1.11 B | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
63.6 M | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
207 M | - | -6.00 % | $ 238 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
2.6 B | $ 3.37 | 4.66 % | $ 568 M |  Singapore |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
164 M | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
485 M | - | 0.38 % | $ 12.9 M |  Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
40.9 M | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
230 M | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
1.57 B | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
8.29 M | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
1.67 B | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
24.2 M | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
4.79 B | - | - | $ 6.81 B | Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
813 M | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
2.65 M | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
42.4 B | $ 928.5 | 3.77 % | $ 56.9 B |  Niderland |
|
XBiotech
XBIT
|
70.4 M | $ 1.88 | 0.53 % | $ 57.3 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
80.6 M | - | -2.54 % | $ 57.2 M | USA |
 |
Xencor
XNCR
|
892 M | $ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
759 M | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
236 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
262 M | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
419 M | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
4.37 M | $ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
1.23 B | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
1.1 B | - | - | $ 1.94 B | Canada |
 |
Exicure
XCUR
|
29 M | $ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Urovant Sciences Ltd.
UROV
|
273 B | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
6.89 B | - | - | $ 10.9 B | USA |